norelgestromin: Clinical Trials

11 trials of norelgestromin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 4 Phase 3, 3 Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 13Completed 3
Phase 42Completed 2
Not applicable1Completed 1
Phase 21Completed 1

Follow norelgestromin: new trials by email Literature Review of norelgestromin trials Research Report on norelgestromin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Birth Control Patch Study
Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016), Norelgestromin/Ethinylestradiol (EVRA) - Contraception
Phase 3CompletedBayer3932009-05-012014-04-02
Bioequivalence Study of Patches With Different Equilibration Profiles
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system. - Female Contraception
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.422004-05-012011-06-08
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.602004-05-012011-06-08
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
norelgestromin + ethinyl estradiol - Contraception, Female Contraception
Phase 4CompletedJanssen Pharmaceutica N.V., Belgium7782003-07-012010-11-16
Birth Control Pill vs Birth Control Patch Study
Ethinyl estradiol and norgestimate, Ethinyl estradiol and norelgestromin - Venous Thrombosis
Not applicableCompletedUniversity of Vermont242003-04-012007-11-07
An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method
norelgestromin; ethinyl estradiol - Female Contraception
Phase 4CompletedJanssen-Ortho Inc., Canada4052002-10-012010-03-26
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.342002-08-012011-06-08
A Study of Efficacy and Safety With the Transdermal Contraceptive System.
norelgestromin + ethinyl estradiol - Contraception, Female Contraception
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.17511997-11-012010-11-17
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.
norelgestromin + ethinyl estradiol; mercilon - Contraception
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.15171997-10-012011-06-08
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
norelgestromin + ethinyl estradiol; triphasil. - Contraception, Female Contraception
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.14941997-01-012011-06-08
An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen
norelgestromin/ethinyl estradiol - Metrorrhagia
Phase 2CompletedMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.2392011-07-01

Conditions studied

Hemorrhage (1)  ·  Metrorrhagia (1)  ·  Venous Thrombosis (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6)  ·  Bayer (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Janssen-Ortho Inc., Canada (1)  ·  McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. (1)  ·  University of Vermont (1)

Countries

Austria (1)  ·  Czechia (1)  ·  Netherlands (1)

Top investigators

Julia V Johnson, MD (1)

Results publications

PMID 11849631, PMID 11849634, PMID 11704172, PMID 15932834, PMID 15937609, PMID 15950671, PMID 18238963, PMID 25453582

NIH funding

2008 (1)